Literature DB >> 23617517

Evaluation of perfusion CT in grading and prognostication of high-grade gliomas at diagnosis: a pilot study.

Jai Jai Shiva Shankar1, John Woulfe, Vasco Da Silva, Thanh B Nguyen.   

Abstract

OBJECTIVE: Differentiation of grade 3 astrocytoma from glioblastoma multiforme can be difficult with conventional structural imaging but is important for prognosis. The purpose of this study was to assess perfusion CT in differentiating high-grade gliomas (HGGs) and their role in prognosis in the care of patients with HGG. SUBJECTS AND METHODS: Twenty patients with previously untreated HGG underwent prospective evaluation with perfusion CT. Permeability surface area product (PS) and cerebral blood volume (CBV) were calculated by the deconvolution method and were compared between HGGs with Student two-sample t tests. Receiver operating characteristic curves were generated for PS, CBV, and the conjoint factor PS + CBV. Cox regression analysis was used to correlate these parameters with patient survival over a follow-up period. Hazard ratios were calculated, and Kaplan-Meier survival curves were drawn.
RESULTS: There was a significant difference between grade 3 and grade 4 gliomas for PS (p = 0.022) and PS + CBV (p = 0.019) but not for CBV alone (p = 0.411). Receiver operating characteristic analyses showed that PS (area under the curve [AUC], 0.72) and CBV + PS (AUC, 0.73) can be used to differentiate grade 3 from grade 4 gliomas but that CBV alone cannot be so used (AUC, 0.54). There was a significant relation between patient outcome and age (p = 0.034) and CBV + PS (p = 0.048). Patients with HGG and a CBV + PS greater than 9 had a poor outcome (hazard ratio, 6.00).
CONCLUSION: PS and CBV + PS can be used to differentiate grade 3 from grade 4 gliomas. The outcome of patients with HGG depends on age and CBV + PS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23617517     DOI: 10.2214/AJR.12.8967

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  7 in total

1.  Survival prediction in high-grade gliomas using CT perfusion imaging.

Authors:  Timothy Pok Chi Yeung; Yong Wang; Wenqing He; Benedetta Urbini; Roberta Gafà; Linda Ulazzi; Slav Yartsev; Glenn Bauman; Ting-Yim Lee; Enrico Fainardi
Journal:  J Neurooncol       Date:  2015-04-11       Impact factor: 4.130

2.  Preoperative prognostic value of dynamic contrast-enhanced MRI-derived contrast transfer coefficient and plasma volume in patients with cerebral gliomas.

Authors:  T B Nguyen; G O Cron; J F Mercier; C Foottit; C H Torres; S Chakraborty; J Woulfe; G H Jansen; J M Caudrelier; J Sinclair; M J Hogan; R E Thornhill; I G Cameron
Journal:  AJNR Am J Neuroradiol       Date:  2014-06-19       Impact factor: 3.825

3.  Correlation between CT perfusion and clinico-pathological features in prostate cancer: a prospective study.

Authors:  Elżbieta Łuczyńska; Sylwia Heinze-Paluchowska; Paweł Blecharz; Barbara Jereczek-Fossa; Giuseppe Petralia; Massimo Bellomi; Andrzej Stelmach
Journal:  Med Sci Monit       Date:  2015-01-13

4.  Perfusion CT is a valuable diagnostic method for prostate cancer: a prospective study of 94 patients.

Authors:  Elzbieta Luczynska; Pawel Blecharz; Sonia Dyczek; Andrzej Stelmach; Giuseppe Petralia; Massimo Bellomi; Barbara Alicja Jereczek-Fossa; Jerzy Jakubowicz
Journal:  Ecancermedicalscience       Date:  2014-10-27

Review 5.  Quantitative Perfusion and Permeability Biomarkers in Brain Cancer from Tomographic CT and MR Images.

Authors:  Armin Eilaghi; Timothy Yeung; Christopher d'Esterre; Glenn Bauman; Slav Yartsev; Jay Easaw; Enrico Fainardi; Ting-Yim Lee; Richard Frayne
Journal:  Biomark Cancer       Date:  2016-07-03

6.  Perfusion CT detects alterations in local cerebral flow of glioma related to IDH, MGMT and TERT status.

Authors:  Ke Wang; Yeming Li; Haiyang Cheng; Shenjie Li; Wei Xiang; Yang Ming; Ligang Chen; Jie Zhou
Journal:  BMC Neurol       Date:  2021-11-24       Impact factor: 2.474

7.  Serum microRNA-210 as a potential noninvasive biomarker for the diagnosis and prognosis of glioma.

Authors:  N-s Lai; D-g Wu; X-g Fang; Y-c Lin; S-s Chen; Z-b Li; S-s Xu
Journal:  Br J Cancer       Date:  2015-03-31       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.